Mary Ann Comunale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mary Ann Comunale has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Samuel Haslund-Gourley
Department of Microbiology and Immunology and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
4 shared publications Brian Wigdahl
Department of Microbiology and Immunology and the Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
3 shared publications- Brian Wigdahl
Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
3 shared publications - Jintong Hou
Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, 19104, USA
3 shared publications Anand S. Mehta
Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States
2 shared publicationsBenjamin Haslund-Gourley
Department of Microbiology and Immunology/Department of Medicine/Department of Epidemiology & Biostatistics, Drexel University, Philadelphia, PA, United States
2 shared publications
Latest Publications
- Open Access
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1604388
Baseline predictors for 28-day COVID-19 severity and mortality among hospitalized patients: results from the IMPACC study
Introduction: The coronavirus disease 2019 (COVID-19) pandemic threatened public health and placed a significant burden on medical resources. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study collected clinical, demographic, blood cytometry, serum receptor-binding domain (RBD) antibody titers, metabolomics, targeted proteomics, nasal metagenomics, Olink, nasal viral load, autoantibody, SARS-CoV-2 antibody titers, and nasal and peripheral blood mononuclear cell (PBMC) transcriptomics data from patients hospitalized with COVID-19. The aim of this study is to select baseline biomarkers and build predictive models for 28-day in-hospital COVID-19 severity and mortality with most predictive variables while prioritizing routinely collected variables.Methods: We analyzed 1102 hospitalized COVID-19 participants. We used the lasso and forward selection to select top predictors for severity and mortality, and built predictive models based on balanced training data. We then validated the models on testing data.Results: Severity was best predicted by the baseline SpO2/FiO2 ratio obtained from COVID-19 patients (test AUC: 0.874). Adding patient age, BMI, FGF23, IL-6, and LTA to the disease severity prediction model improves the test AUC by an additional 3%. The clinical mortality prediction model using SpO2/FiO2 ratio, age, and BMI resulted in a test AUC of 0.83. Adding laboratory results such as TNFRSF11B and plasma ribitol count increased the prediction model by 3.5%. The severity and mortality prediction models developed outperform the Sequential Organ Failure Assessment (SOFA) score among inpatients and perform similarly to the SOFA score among ICU patients.Conclusion: This study identifies clinical data and laboratory biomarkers of COVID-19 severity and mortality using machine learning models. The study identifies SpO2/FiO2 ratio to be the most important predictor for both severity and mortality. Several biomarkers were identified to modestly improve the predictions. The results also provide a baseline of SARS-CoV-2 infection during the early stages of the coronavirus emergence and can serve as a baseline for future studies that inform how the genetic evolution of the coronavirus affects the host response to new variants.
- 4 July 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1604388
Open AccessBaseline predictors for 28-day COVID-19 severity and mortality among hospitalized patients: results from the IMPACC study
Introduction: The coronavirus disease 2019 (COVID-19) pandemic threatened public health and placed a significant burden on medical resources. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study collected clinical, demographic, blood cytometry, serum receptor-binding domain (RBD) antibody titers, metabolomics, targeted proteomics, nasal metagenomics, Olink, nasal viral load, autoantibody, SARS-CoV-2 antibody titers, and nasal and peripheral blood mononuclear cell (PBMC) transcriptomics data from patients hospitalized with COVID-19. The aim of this study is to select baseline biomarkers and build predictive models for 28-day in-hospital COVID-19 severity and mortality with most predictive variables while prioritizing routinely collected variables.Methods: We analyzed 1102 hospitalized COVID-19 participants. We used the lasso and forward selection to select top predictors for severity and mortality, and built predictive models based on balanced training data. We then validated the models on testing data.Results: Severity was best predicted by the baseline SpO2/FiO2 ratio obtained from COVID-19 patients (test AUC: 0.874). Adding patient age, BMI, FGF23, IL-6, and LTA to the disease severity prediction model improves the test AUC by an additional 3%. The clinical mortality prediction model using SpO2/FiO2 ratio, age, and BMI resulted in a test AUC of 0.83. Adding laboratory results such as TNFRSF11B and plasma ribitol count increased the prediction model by 3.5%. The severity and mortality prediction models developed outperform the Sequential Organ Failure Assessment (SOFA) score among inpatients and perform similarly to the SOFA score among ICU patients.Conclusion: This study identifies clinical data and laboratory biomarkers of COVID-19 severity and mortality using machine learning models. The study identifies SpO2/FiO2 ratio to be the most important predictor for both severity and mortality. Several biomarkers were identified to modestly improve the predictions. The results also provide a baseline of SARS-CoV-2 infection during the early stages of the coronavirus emergence and can serve as a baseline for future studies that inform how the genetic evolution of the coronavirus affects the host response to new variants.
- 29 March 2024
- Published by Drexel University Libraries
Glycosylation of immunoglobulins
Glycoproteins are post-translationally modified proteins containing branched sugar structures referred to as glycans. One major class of glycoproteins are the immunoglobulins. Immunoglobulins play a key role in the adaptive immune response and require glycosylation in the Golgi apparatus before release into circulation. The size, charge, and shape of glycans added to immunoglobulins determine half-life, effector function, and Fc receptor binding affinity. In the laboratory, classes of immunoglobulins can be isolated from patient blood and analyzed for glycan content using lectin, chromatographic, and mass spectrometry methods. In this thesis, glycans from human IgG and IgM are analyzed for changes during health and disease states. We elected to study Lyme disease because the host response to Lyme disease had not been characterized using a glycomic approach. We hypothesized that the host antibody glycomic response to acute Lyme disease would reveal more information about how the host immune response is mounted. Further, we hypothesized that this study could reveal mechanisms of host adaptive immune system evasion by the Lyme disease bacterium. We first asked: what immunoglobulin glycan alterations are associated with acute Lyme disease infection in humans? Here, we demonstrate IgG and IgM glycans produced in response to acute Lyme disease contain elevated levels of galactose and sialic acid. Next, we link the changes in immunoglobulin glycan profiles observed during acute Lyme disease to the functional impairment of IgG to signal for antibody-dependent cellular cytotoxicity. Following antibiotic therapy for Lyme disease, we demonstrate antibody glycosylation decreased the sialic acid content to reflect the resolution of Lyme disease. Later in this thesis, we characterize the glycan-associated serological response to COVID-19 by studying hospitalized patients infected from the Immunophenotyping assessment in a COVID-19 cohort. Studies of the COVID-19 glycomic response were previously limited to IgG glycans. We sought to characterize the glycomic response of both IgG and IgM to gain more insight into the adaptive immune response during COVID-19. We hypothesized that glycans on IgM would stratify patients with nonsevere versus severe COVID-19 better than IgG glycans. Further, we hypothesized that IgM glycans characterization would provide more insight into the acute host response to the viral infection. Here, we report significant differences in the IgG and IgM glycan profiles - particularly the ability of IgM glycans to aid in the stratification of nonsevere versus severe COVID-19 patients. We next hypothesized that the IgM glycans were modulating IgM- directed complement deposition. To test this, we developed an antigen-specific assay using purified IgM with and without sialidase digestions. Using this assay, we demonstrate a potential mechanism of the sialic acid glycans on IgM to promote complement deposition in severely infected COVID-19 patients. In conclusion, this thesis examines immunoglobulin glycosylation during human adaptive immune responses and links these glycan changes to modulated immunoglobulin effector function. In the case of acute Lyme disease, the sialic acid on antigen-specific IgG responding to Lyme disease impairs the induction of ADCC signaling. This impairment could be one mechanism of host immune evasion benefiting the Lyme disease bacterium. In contrast, elevated levels of sialic acid on IgM isolated from severe COVID-19 infections were associated with increased rates of complement deposition. Our data suggest this elevated IgM sialic acid could promote acute respiratory distress due to elevated complement deposition in the lung epithelia and endothelia of severe COVID-19 patients. Future studies should determine which pathways and cytokines are responsible for shifting the glycosylation of IgG and IgM during acute immune responses.
- 29 March 2024
- Published by Drexel University Libraries
Glycosylation of immunoglobulins
Glycoproteins are post-translationally modified proteins containing branched sugar structures referred to as glycans. One major class of glycoproteins are the immunoglobulins. Immunoglobulins play a key role in the adaptive immune response and require glycosylation in the Golgi apparatus before release into circulation. The size, charge, and shape of glycans added to immunoglobulins determine half-life, effector function, and Fc receptor binding affinity. In the laboratory, classes of immunoglobulins can be isolated from patient blood and analyzed for glycan content using lectin, chromatographic, and mass spectrometry methods. In this thesis, glycans from human IgG and IgM are analyzed for changes during health and disease states. We elected to study Lyme disease because the host response to Lyme disease had not been characterized using a glycomic approach. We hypothesized that the host antibody glycomic response to acute Lyme disease would reveal more information about how the host immune response is mounted. Further, we hypothesized that this study could reveal mechanisms of host adaptive immune system evasion by the Lyme disease bacterium. We first asked: what immunoglobulin glycan alterations are associated with acute Lyme disease infection in humans? Here, we demonstrate IgG and IgM glycans produced in response to acute Lyme disease contain elevated levels of galactose and sialic acid. Next, we link the changes in immunoglobulin glycan profiles observed during acute Lyme disease to the functional impairment of IgG to signal for antibody-dependent cellular cytotoxicity. Following antibiotic therapy for Lyme disease, we demonstrate antibody glycosylation decreased the sialic acid content to reflect the resolution of Lyme disease. Later in this thesis, we characterize the glycan-associated serological response to COVID-19 by studying hospitalized patients infected from the Immunophenotyping assessment in a COVID-19 cohort. Studies of the COVID-19 glycomic response were previously limited to IgG glycans. We sought to characterize the glycomic response of both IgG and IgM to gain more insight into the adaptive immune response during COVID-19. We hypothesized that glycans on IgM would stratify patients with nonsevere versus severe COVID-19 better than IgG glycans. Further, we hypothesized that IgM glycans characterization would provide more insight into the acute host response to the viral infection. Here, we report significant differences in the IgG and IgM glycan profiles - particularly the ability of IgM glycans to aid in the stratification of nonsevere versus severe COVID-19 patients. We next hypothesized that the IgM glycans were modulating IgM- directed complement deposition. To test this, we developed an antigen-specific assay using purified IgM with and without sialidase digestions. Using this assay, we demonstrate a potential mechanism of the sialic acid glycans on IgM to promote complement deposition in severely infected COVID-19 patients. In conclusion, this thesis examines immunoglobulin glycosylation during human adaptive immune responses and links these glycan changes to modulated immunoglobulin effector function. In the case of acute Lyme disease, the sialic acid on antigen-specific IgG responding to Lyme disease impairs the induction of ADCC signaling. This impairment could be one mechanism of host immune evasion benefiting the Lyme disease bacterium. In contrast, elevated levels of sialic acid on IgM isolated from severe COVID-19 infections were associated with increased rates of complement deposition. Our data suggest this elevated IgM sialic acid could promote acute respiratory distress due to elevated complement deposition in the lung epithelia and endothelia of severe COVID-19 patients. Future studies should determine which pathways and cytokines are responsible for shifting the glycosylation of IgG and IgM during acute immune responses.
- Open Access
- 23 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104979
Host glycosylation of immunoglobulins impairs the immune response to acute Lyme disease
- 23 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104979
Open AccessHost glycosylation of immunoglobulins impairs the immune response to acute Lyme disease
- Open Access
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-19
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15  (1) , 1-19
Open AccessIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- Open Access
- 2 June 2023
- Published by Springer Nature in Research Square
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human SARS-CoV-2, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during acute viral infection in humans. In vitro evidence suggests that the glycosylation of IgM inhibits T cell proliferation and alters complement activation rates. The analysis of IgM N-glycosylation from healthy controls and hospitalized COVID-19 patients reveals that mannosylation and sialyation levels associate with COVID-19 severity. Specifically, we find increased di- and tri-sialylated glycans and altered mannose glycans in total serum IgM in severe COVID-19 patients when compared to moderate COVID-19 patients. This is in direct contrast with the decrease of sialic acid found on the serum IgG from the same cohorts. Moreover, the degree of mannosylation and sialylation correlated significantly with markers of disease severity: D-dimer, BUN, creatinine, potassium, and early anti-COVID-19 amounts of IgG, IgA, and IgM. Further, IL-16 and IL-18 cytokines showed similar trends with the amount of mannose and sialic acid present on IgM, implicating these cytokines' potential to impact glycosyltransferase expression during IgM production. When examining PBMC mRNA transcripts, we observe a decrease in the expression of Golgi mannosidases that correlates with the overall reduction in mannose processing we detect in the IgM N-glycosylation profile. Importantly, we found that IgM contains alpha-2,3 linked sialic acids in addition to the previously reported alpha-2,6 linkage. We also report that antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients. Taken together, this work links the immunoglobulin M N-glycosylation with COVID-19 severity and highlights the need to understand the connection between IgM glycosylation and downstream immune function during human disease.
- 2 June 2023
- Published by Springer Nature in Research Square
Open AccessIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human SARS-CoV-2, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during acute viral infection in humans. In vitro evidence suggests that the glycosylation of IgM inhibits T cell proliferation and alters complement activation rates. The analysis of IgM N-glycosylation from healthy controls and hospitalized COVID-19 patients reveals that mannosylation and sialyation levels associate with COVID-19 severity. Specifically, we find increased di- and tri-sialylated glycans and altered mannose glycans in total serum IgM in severe COVID-19 patients when compared to moderate COVID-19 patients. This is in direct contrast with the decrease of sialic acid found on the serum IgG from the same cohorts. Moreover, the degree of mannosylation and sialylation correlated significantly with markers of disease severity: D-dimer, BUN, creatinine, potassium, and early anti-COVID-19 amounts of IgG, IgA, and IgM. Further, IL-16 and IL-18 cytokines showed similar trends with the amount of mannose and sialic acid present on IgM, implicating these cytokines' potential to impact glycosyltransferase expression during IgM production. When examining PBMC mRNA transcripts, we observe a decrease in the expression of Golgi mannosidases that correlates with the overall reduction in mannose processing we detect in the IgM N-glycosylation profile. Importantly, we found that IgM contains alpha-2,3 linked sialic acids in addition to the previously reported alpha-2,6 linkage. We also report that antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients. Taken together, this work links the immunoglobulin M N-glycosylation with COVID-19 severity and highlights the need to understand the connection between IgM glycosylation and downstream immune function during human disease.
- Open Access
- 7 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13  (6) , 1016
IgG N-glycan Signatures as Potential Diagnostic and Prognostic Biomarkers
IgG N-glycans are an emerging source of disease-specific biomarkers. Over the last decade, the continued development of glycomic databases and the evolution of glyco-analytic methods have resulted in increased throughput, resolution, and sensitivity. IgG N-glycans promote adaptive immune responses through antibody-dependent cellular cytotoxicity (ADCC) and complement activation to combat infection or cancer and promote autoimmunity. In addition to the functional assays, researchers are examining the ability of protein-specific glycosylation to serve as biomarkers of disease. This literature review demonstrates that IgG N-glycans can discriminate between healthy controls, autoimmune disease, infectious disease, and cancer with high sensitivity. The literature also indicates that the IgG glycosylation patterns vary across disease state, thereby supporting their role as specific biomarkers. In addition, IgG N-glycans can be collected longitudinally from patients to track treatment responses or predict disease reoccurrence. This review focuses on IgG N-glycan profiles applied as diagnostics, cohort discriminators, and prognostics. Recent successes, remaining challenges, and upcoming approaches are critically discussed.
- 7 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13  (6) , 1016
Open AccessIgG N-glycan Signatures as Potential Diagnostic and Prognostic Biomarkers
IgG N-glycans are an emerging source of disease-specific biomarkers. Over the last decade, the continued development of glycomic databases and the evolution of glyco-analytic methods have resulted in increased throughput, resolution, and sensitivity. IgG N-glycans promote adaptive immune responses through antibody-dependent cellular cytotoxicity (ADCC) and complement activation to combat infection or cancer and promote autoimmunity. In addition to the functional assays, researchers are examining the ability of protein-specific glycosylation to serve as biomarkers of disease. This literature review demonstrates that IgG N-glycans can discriminate between healthy controls, autoimmune disease, infectious disease, and cancer with high sensitivity. The literature also indicates that the IgG glycosylation patterns vary across disease state, thereby supporting their role as specific biomarkers. In addition, IgG N-glycans can be collected longitudinally from patients to track treatment responses or predict disease reoccurrence. This review focuses on IgG N-glycan profiles applied as diagnostics, cohort discriminators, and prognostics. Recent successes, remaining challenges, and upcoming approaches are critically discussed.
- Open Access
Large-Scale Sequencing of Borreliaceae for the Construction of Pan-Genomic-Based Diagnostics
The acceleration of climate change has been associated with an alarming increase in the prevalence and geographic range of tick-borne diseases (TBD), many of which have severe and long-lasting effects—particularly when treatment is delayed principally due to inadequate diagnostics and lack of physician suspicion. Moreover, there is a paucity of treatment options for many TBDs that are complicated by diagnostic limitations for correctly identifying the offending pathogens. This review will focus on the biology, disease pathology, and detection methodologies used for the Borreliaceae family which includes the Lyme disease agent Borreliella burgdorferi. Previous work revealed that Borreliaceae genomes differ from most bacteria in that they are composed of large numbers of replicons, both linear and circular, with the main chromosome being the linear with telomeric-like termini. While these findings are novel, additional gene-specific analyses of each class of these multiple replicons are needed to better understand their respective roles in metabolism and pathogenesis of these enigmatic spirochetes. Historically, such studies were challenging due to a dearth of both analytic tools and a sufficient number of high-fidelity genomes among the various taxa within this family as a whole to provide for discriminative and functional genomic studies. Recent advances in long-read whole-genome sequencing, comparative genomics, and machine-learning have provided the tools to better understand the fundamental biology and phylogeny of these genomically-complex pathogens while also providing the data for the development of improved diagnostics and therapeutics.
Open AccessLarge-Scale Sequencing of Borreliaceae for the Construction of Pan-Genomic-Based Diagnostics
The acceleration of climate change has been associated with an alarming increase in the prevalence and geographic range of tick-borne diseases (TBD), many of which have severe and long-lasting effects—particularly when treatment is delayed principally due to inadequate diagnostics and lack of physician suspicion. Moreover, there is a paucity of treatment options for many TBDs that are complicated by diagnostic limitations for correctly identifying the offending pathogens. This review will focus on the biology, disease pathology, and detection methodologies used for the Borreliaceae family which includes the Lyme disease agent Borreliella burgdorferi. Previous work revealed that Borreliaceae genomes differ from most bacteria in that they are composed of large numbers of replicons, both linear and circular, with the main chromosome being the linear with telomeric-like termini. While these findings are novel, additional gene-specific analyses of each class of these multiple replicons are needed to better understand their respective roles in metabolism and pathogenesis of these enigmatic spirochetes. Historically, such studies were challenging due to a dearth of both analytic tools and a sufficient number of high-fidelity genomes among the various taxa within this family as a whole to provide for discriminative and functional genomic studies. Recent advances in long-read whole-genome sequencing, comparative genomics, and machine-learning have provided the tools to better understand the fundamental biology and phylogeny of these genomically-complex pathogens while also providing the data for the development of improved diagnostics and therapeutics.
- Open Access
- 5 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 949118
Acute Lyme disease IgG N-linked glycans contrast the canonical inflammatory signature
Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb). Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion. Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system. Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized. In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days. Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature. This unexpected result is in direct contrast to what is reported for other inflammatory diseases. Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
- 5 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 949118
Open AccessAcute Lyme disease IgG N-linked glycans contrast the canonical inflammatory signature
Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato (Bb). Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion. Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system. Immunoglobulin G (IgG) N-glycan responses to LD have not been characterized. In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days. Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature. This unexpected result is in direct contrast to what is reported for other inflammatory diseases. Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%.
- Open Access
Lyme Disease IgG N-linked Glycans Contrast the Canonical Inflammatory Signature
Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato . Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion. Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system. IgG N-glycan responses to LD have not been characterized. In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days. Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature. This unexpected result is in direct contrast to what is reported for other inflammatory diseases. Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%. Author summary: The causative agent of Lyme disease (LD), Borrelia burgdorferi sensu lato (Bb), is transmitted from an infected Ixodes tick into the human host dermis during the tick’s blood meal. Currently, LD is the most prevalent vector-borne disease in the US, with an estimated 476,000 annual cases. LD diagnostics rely on patient seroconversion against Bb antigens, and these tests cannot distinguish between an acute patient compared to a patient previously treated for LD. With the goal of identifying novel biomarkers associated specifically with LD infections, we analyzed the glycoprotein Immunoglobulin G (IgG) N-glycan signatures from healthy control, acute LD, and a second time point composed of the same LD patients after antibiotic therapy. We found acute LD IgG N-glycan signatures were significantly different from the canonical pro-inflammatory profile associated with most inflammatory diseases. The dramatic shifts observed in the acute LD time point were further altered at the treated time point. IgG N-glycan signature data was employed to discriminate between acute LD and healthy controls. In addition, IgG N-glycan signatures distinguished patients who completed antibiotic therapy from the acute LD timepoint. Our study will contribute to the accurate and prompt treatment of LD patients and reveals a new research avenue of immune dysregulation associated with LD. Graphical
Open AccessLyme Disease IgG N-linked Glycans Contrast the Canonical Inflammatory Signature
Lyme disease (LD) infection is caused by Borrelia burgdorferi sensu lato . Due to the limited presence of this pathogen in the bloodstream in humans, diagnosis of LD relies on seroconversion. Immunoglobulins produced in response to infection are differentially glycosylated to promote or inhibit downstream inflammatory responses by the immune system. IgG N-glycan responses to LD have not been characterized. In this study, we analyzed IgG N-glycans from cohorts of healthy controls, acute LD patient serum, and serum collected after acute LD patients completed a 2- to 3-week course of antibiotics and convalesced for 70-90 days. Results indicate that during the acute phase of Bb infection, IgG shifts its glycosylation profile to include structures that are not associated with the classic proinflammatory IgG N-glycan signature. This unexpected result is in direct contrast to what is reported for other inflammatory diseases. Furthermore, IgG N-glycans detected during acute LD infection discriminated between control, acute, and treated cohorts with a sensitivity of 75-100% and specificity of 94.7-100%. Author summary: The causative agent of Lyme disease (LD), Borrelia burgdorferi sensu lato (Bb), is transmitted from an infected Ixodes tick into the human host dermis during the tick’s blood meal. Currently, LD is the most prevalent vector-borne disease in the US, with an estimated 476,000 annual cases. LD diagnostics rely on patient seroconversion against Bb antigens, and these tests cannot distinguish between an acute patient compared to a patient previously treated for LD. With the goal of identifying novel biomarkers associated specifically with LD infections, we analyzed the glycoprotein Immunoglobulin G (IgG) N-glycan signatures from healthy control, acute LD, and a second time point composed of the same LD patients after antibiotic therapy. We found acute LD IgG N-glycan signatures were significantly different from the canonical pro-inflammatory profile associated with most inflammatory diseases. The dramatic shifts observed in the acute LD time point were further altered at the treated time point. IgG N-glycan signature data was employed to discriminate between acute LD and healthy controls. In addition, IgG N-glycan signatures distinguished patients who completed antibiotic therapy from the acute LD timepoint. Our study will contribute to the accurate and prompt treatment of LD patients and reveals a new research avenue of immune dysregulation associated with LD. Graphical
- 16 July 2021
- Published by Drexel University Libraries
Getting Into the Game
Play learning is natural to all human beings and has been a part human culture since ancient time. Teaching children through games is widely accepted, but as we become adults, learning takes on a more serious construction. Research has shown that game based learning can be motivational and result in positive learning outcomes for all levels of learning. However, higher education has been slow to acceptance and use. By taking a closer look into the stories of early adopters that implemented digital games into higher education, this study utilized a multi-case study approach to understand the basis for the decision to use games, and the faculty experience during the game design and implementation phases. Results indicate that the higher education early adopter's decision to use games was a creative solution to resolve conflicts that occurred in their classrooms, and they were intrinsically motivated even though they would not necessarily consider themselves to be "gamers." Each participant received support from their administrators and peers and described their experience as positive. Recommendations for administrators and faculty interested in pursuing digital game based learning in higher education and for future research are provided.
- 16 July 2021
- Published by Drexel University Libraries
Getting Into the Game
Play learning is natural to all human beings and has been a part human culture since ancient time. Teaching children through games is widely accepted, but as we become adults, learning takes on a more serious construction. Research has shown that game based learning can be motivational and result in positive learning outcomes for all levels of learning. However, higher education has been slow to acceptance and use. By taking a closer look into the stories of early adopters that implemented digital games into higher education, this study utilized a multi-case study approach to understand the basis for the decision to use games, and the faculty experience during the game design and implementation phases. Results indicate that the higher education early adopter's decision to use games was a creative solution to resolve conflicts that occurred in their classrooms, and they were intrinsically motivated even though they would not necessarily consider themselves to be "gamers." Each participant received support from their administrators and peers and described their experience as positive. Recommendations for administrators and faculty interested in pursuing digital game based learning in higher education and for future research are provided.